The report “In-Vitro
Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical,
Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications
(Systemic, Dermal, Ocular),Method (Cellular Assay, Ex vivo, In Silico) - Global
Forecast to 2018”, The global market will reach $17,227 million by 2018
growing at a double-digit CAGR during the forecast period (2013–2018).
Browse 67 market data tables, 25 figures spread through 246 pages and in-depth TOC on “In-Vitro Toxicity Testing Market”
Early buyers will receive 10%
customization on this report.
The global market is segmented by industry, technology, method,
application and geography. Based on industry, the market is further segmented
into diagnostics, pharmaceuticals, chemicals, cosmetics, and food.
Pharmaceutical industry secured the largest market share whereas cosmetics
industry was the fastest growing industry than the rest. The inclination towards
detection of toxicity during earlier stages of development is propelling the
growth of pharmaceutical industry. Also, the support of regulatory authorities
to use in vitro and in silico methods in place of animal testing for gathering
toxicological information is driving the cosmetic industry.
Talk to Our Research Analysts for More Info@
Based on technology, the market is segmented into cell culture, high
throughput screening, cellular imaging, and omics technologies. Cell culture
technology that occupies the largest market share will also register maximum
growth rate. The evolution and advancement is leading to introduction of new
technologies that can better predict toxicity levels and translate in vitro
results into significant in vivo effects.
The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays held the largest market share in 2013 and the market is bound to grow at a double digit CAGR during the forecast period (2013–2018). These assays provide the capability to detect and measure cell viability, functionality, and growth. Cellular assays are used as bio markers which have capacity to predict the biological properties of potential drug compounds.
Get The Sample Copy Of This Report:
Under the applications, systemic toxicity testing was the largest
segment in 2013 and will grow at the highest CAGR between 2013 and 2018. Both
cardiotoxicity and liver toxicity under systemic toxicity are the key reasons
for drug attrition. The increasing focus on detection of toxicity in earlier
stages of development is leading to persistent requirements for human
cell-based in vitro models.
Geographic analysis reveals that Europe commanded the largest share of the global in vitro toxicity testing market in 2013. This was credited to the support provided by the European government for anti-animal testing laws. The directives set by the government has further put ban on the production and sale of all animal tested cosmetics across the continent.
Globally, the market will be driven by increasing acceptance of in
vitro toxicity testing methods by regulatory authorities as alternatives to in
vivo testing. This has been primarily driven by demand for toxicological
information on chemicals that are both existing and newly introduced into the
market. The new advances in the in vitro toxicology testing have presented a
wide range of new technologies that help in investigating the adverse effects
of environmental agents in a more mechanistic, less expensive, and time saving
Organizations such as REACH foresee that more results of in
vitro and in silico methods will be included in risk assessment which will
promote the use of in-vitro methods for toxicology testing. The emerging
countries in Asia, such as China and India, will witness high growth on account
of low cost offered by these countries as well as the economic stability
observed within these countries.
The market is a highly fragmented one. The dominant players in this market are Agilent Technologies (U.S.), Alere, Inc. (U.S.), Bio-Rad (U.S.), BioReliance (Sigma Aldrich) (U.S.), Catalent Pharma Solutions (U.S.), Charles River Laboratories (U.S.), Covance (U.S.), Cyprotex (U.K.), Eurofins Scientific, Inc. (U.S.), GE Healthcare (U.K.), Life Technologies Corporation (Thermo Fisher Scientific) (U.S.), and Quest Diagnostics (U.S.).
is the world’s No. 2 firm in terms of annually published premium market
research reports. Serving 1700 global fortune enterprises with more than 1200
premium studies in a year, M&M is catering to a multitude of clients across
8 different industrial verticals. We specialize in consulting assignments and
business research across high growth markets, cutting edge technologies and
newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are
tracking global high growth markets following the "Growth Engagement Model
– GEM". The GEM aims at proactive collaboration with the clients to
identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors.
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche markets.
The new included chapters on Methodology and Benchmarking presented with high
quality analytical infographics in our reports gives complete visibility of how
the numbers have been arrived and defend the accuracy of the numbers.
MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.
Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets